Background: Patient-reported outcomes (PROs) are used to assess benefit-risk in drug development. The relationship between PROs and clinical outcomes is not well understood. We aim to elucidate the relationships between changes in PRO measures and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC).
Introduction
In many patients with metastatic castration-resistant prostate cancer (mCRPC), complications from metastases and treatmentrelated toxicities can lead to rapid onset of pain, fatigue, and diminished physical well-being (PWB) and functional well-being (FWB), which can have a negative impact on overall healthrelated quality of life (HRQoL) [1, 2] . Studies in a wide variety of malignancies demonstrate the prognostic value of patientreported outcomes (PROs) measured at baseline [3] . However, the association between postbaseline changes in PRO measures and clinical outcomes is not known. Thus, evaluation of changes in PROs is important for establishing an improved clinical understanding of a patient's cancer experience and treatment.
A modification of the Consolidated Standards of Reporting Trials (CONSORT) statement was developed to improve reporting of PRO data from clinical trials. The CONSORT PRO extension was designed to facilitate meaningful interpretation of trial results and better inform therapeutic decision-making and patient care [4] . PROs are becoming increasingly important in cancer drug development [5] , and several treatments for mCRPC (abiraterone acetate plus prednisone, cabazitaxel, enzalutamide and radium-223) now include PRO label claims approved by regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency [1] . Although PROs have been assessed in several recent mCRPC clinical trials in the chemotherapy-naïve and postdocetaxel settings [6] [7] [8] , their relationship with clinical outcomes has not been well studied. Healthcare providers, payers and patients are interested in the clinical meaningfulness of self-reported symptoms, which may affect treatment decisionmaking and future healthcare costs [9] .
COU-AA-301 (clinicaltrials.gov: NCT00638690) and COU-AA-302 (clinicaltrials.gov: NCT00887198) were international, phase III, randomized, double-blind trials of abiraterone acetate (1000 mg/day) plus prednisone (10 mg/day) (hereafter abiraterone-prednisone) versus placebo plus prednisone (hereafter prednisone alone) in postdocetaxel or chemotherapy-naïve patients with mCRPC, respectively [10, 11] . COU-AA-301 enrolled 1195 patients (n ¼ 797 abiraterone-prednisone; n ¼ 398 prednisone alone) who had progressed after docetaxel-based chemotherapy and had an Eastern Cooperative Oncology Group performance status (ECOG PS) 2 [10] . COU-AA-302 enrolled 1088 patients (n ¼ 546 abiraterone-prednisone; n ¼ 542 prednisone alone) who had no prior chemotherapy, were asymptomatic [score, 0 or 1 on Brief Pain Inventory-Short Form (BPI-SF) item 3] or mildly symptomatic (score, 2 or 3 on BPI-SF item 3), had ECOG PS 0 or 1 and had no prior visceral metastases [11] .
The relationships between changes in PROs and subsequent clinical outcomes [overall survival (OS) and radiographic progression-free survival (rPFS)] were explored using the COU-AA-301 and COU-AA-302 datasets. In both trials, tumor assessments and PRO data were collected with regular frequency as prespecified time points in the study protocol. This post hoc analysis was designed to determine whether there was a consistent relationship between changes in PROs and subsequent clinical outcomes. Since PRO questionnaires can be administered with greater frequency and less invasively than tumor assessments, changes in PROs have the potential to inform diagnostic and treatment decisions.
Patients in COU-AA-301 were in poorer health at baseline than those in COU-AA-302 (Table 1) . Therefore, the relationship between clinical outcomes and PROs was assessed in a manner suited to each patient population. In patients from COU-AA-301, the association between PRO improvements and clinical outcomes was evaluated; in patients from COU-AA-302, the association between PRO worsening and clinical outcomes was assessed.
Methods

Patient population
This post hoc analysis included all patients from COU-AA-301 and COU-AA-302, regardless of treatment arm. Prognostic index models by treatment arm have been described for both studies [12, 13] .
The study was conducted according to principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference on Harmonisation. All patients provided written informed consent to participate.
Methods
Relationships between changes in self-reported fatigue (COU-AA-301 only), pain, FWB, PWB and prostate cancer-specific symptoms with clinical time-to-event outcomes (OS and rPFS) were assessed using data from the first 6 months of treatment. Since PROs were not assessed beyond disease progression, the 6-month post-treatment time point was selected because of the likelihood that PRO and clinical data would be available for the largest number of patients. An additional sensitivity analysis was conducted using data from 12 months post-treatment to confirm these results.
In both studies, OS was defined as the time from randomization to death from any cause and radiographic progression was defined as softtissue disease progression according to modified Response Evaluation Criteria in Solid Tumors (with a baseline lymph node of 2.0 cm considered a target lesion) or progression according to bone scans revealing two or more new lesions not consistent with tumor flare. Assessment of rPFS in COU-AA-302 included blinded, independent review of all scheduled and unscheduled tumor response (computed tomography and magnetic resonance imaging) and bone progression (bone scan) data.
Patients completed PRO questionnaires independently during scheduled office visits. Fatigue (COU-AA-301 only) was assessed using the Brief Fatigue Inventory [BFI [14] ; average of items 1 (present fatigue), 2 (usual fatigue level in last 24 h) and 3 (worst fatigue in last 24 h)], with a score range of 0-10 for each. A higher BFI score indicates worse fatigue. Pain was assessed using the BPI-SF [15] : average of items 3 (worst pain in last 24 h), 4 (least pain in last 24 h), 5 (average pain) and 6 (present pain), with a score range of 0-10 for each. Higher BPI-SF score indicates worse pain intensity.
Prostate-specific HRQoL, including pain and fatigue, was assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire [16] . The following scores, derived from the FACT-P, were included in this analysis because they bear conceptual relationship to clinical variables of progression and survival: FWB [subscale of FACTGeneral (FACT-G)] (score range, 0-28), PWB (subscale of FACT-G) (score range, 0-28) and Prostate Cancer Subscale (PCS) (score range, 0-48). Higher scores in each indicate better FWB, PWB or prostate cancer-specific signs and symptoms, respectively (supplementary Appendix S1, available at Annals of Oncology online).
While absolute values of the threshold criteria applied were consistent for both studies, the direction of the change measured (improvement or worsening) was specific to the patient population. In COU-AA-301, the threshold criterion for PRO improvements for fatigue intensity and pain intensity was a decrease 2 points from baseline. The threshold criterion for improvement in PWB, FWB and PCS was an increase 4 points from baseline. In COU-AA-302, the threshold criterion for PRO worsening in pain intensity was an increase 2 points from baseline; the threshold for worsening in FWB, PWB and PCS was a decrease 4 points from baseline. These thresholds were selected because they have been shown to reflect clinically meaningful change [16] .
Statistical methods for PRO analyses of COU-AA-301 and COU-AA-302
To model the relationship between change in PRO score and time to event of interest, Cox proportional hazards regressions were used. The primary analysis was restricted to data from the first 6 months posttreatment; patients who had not died or progressed radiographically at the time of this cutoff were censored.
Changes in PRO scores were entered into the model as binary indicator variables and to reflect whether the threshold criteria were met at any point in the first 6 months of follow-up or post-treatment. Each model was adjusted for age, baseline prostate-specific antigen, Gleason score at initial diagnosis, baseline ECOG PS score, number of prior therapies, number of prior lines of chemotherapy (COU-AA-301 only), time from diagnosis to randomization, geographic region and baseline PRO scores.
In the multivariate analysis, each covariate was forced into the model, then a forward selection method was carried out on the PRO indicator variables. A significance level of 0.05 was required for entry into the multivariate model.
Results
Baseline characteristics were well balanced between the patient populations ( Table 1, supplementary Table S1 , available at Annals of Oncology online).
Six-month results from COU-AA-301
At 6 months post-treatment, there were 213 deaths and 641 radiographic progression events; remaining patients were censored. In each individual model, patients with PRO score improvements had a more favorable clinical time-to-event outcome for OS and rPFS [hazard ratio (HR) < 1] during follow-up versus patients who did not improve. Improvements in fatigue intensity, pain intensity, FWB, PWB and prostate cancer-specific signs and symptoms corresponded to OS (P < 0.0001; Figure 1A ) and rPFS (P < 0.0001; Figure 1B) .
When PRO indicators were analyzed using a forward selection approach, all except pain intensity were significantly associated with OS and added to the multivariate model. Improvements in fatigue intensity, FWB, PWB and prostate cancer-specific signs and symptoms corresponded to 68% (P < 0.001), 44% (P ¼ 0.04), 61% (P ¼ 0.006) and 59% (P < 0.001) reductions in risk of death, respectively. For rPFS, pain intensity, FWB and PWB, improvements were significantly associated with delayed radiographic progression and were added to the multivariate model. Improvements in pain intensity, FWB and PWB corresponded to 33% (P ¼ 0.002), 30% (P ¼ 0.006) and 39% (P < 0.001) reductions in risk of rPFS, respectively. Fatigue intensity and prostate cancer-specific signs and symptoms did not meet the statistical criteria and were not added to the model. 
Twelve-month results from COU-AA-301
There were 511 deaths and 884 radiographic progression events post-treatment. In each individual model, patients with PRO score improvements (supplementary Table S2 , available at Annals of Oncology online) had a reduced risk of death and radiographic progression compared with patients who did not have PRO score improvements. Improvements in fatigue intensity, pain intensity, FWB, PWB and prostate cancer-specific signs and symptoms corresponded to 73%, 59%, 70%, 74% and 66% reductions in risk of death, respectively (P < 0.0001 each). Reductions in risk of radiographic progression were 46%, 47%, 49%, 55% and 42% for these same respective PRO indicators (P < 0.0001 each).
In the multivariate analysis, all PRO indicators except pain intensity were significantly associated with OS and were added to the model (supplementary Table S3 , available at Annals of Oncology online). Fatigue intensity, pain intensity, FWB and PWB improvements were significantly associated with delayed radiographic progression and were added to the model. Prostate cancer-specific signs and symptoms did not meet the criteria and were not added to the model at either 6 or 12 months posttreatment.
Compared with patients whose PRO score did not worsen, patients with PRO score worsening had an increased risk of death and radiographic progression at 6 and 12 months post-treatment (supplementary Table S4 , available at Annals of Oncology online). However, these associations were not as strong as those with PRO score improvements and reduced risk of death and radiographic progression.
Six-month results from COU-AA-302
There were 26 deaths and 316 radiographic progression events in COU-AA-302, and too few deaths within 6 months of follow-up or post-treatment to explore the relationship between PRO and OS.
In individual models, patients with PRO score worsening had a significantly higher risk (HR > 1) of radiographic progression during follow-up versus patients with no PRO score worsening. Worsening pain intensity, FWB, PWB and prostate cancerspecific signs and symptoms corresponded to 68% (P ¼ 0.0002), 35% (P ¼ 0.0249), 108% (P < 0.0001) and 52% (P ¼ 0.0011) higher risk of radiographic progression per investigator review (Figure 2) .
In the multivariate analysis, only worsening PWB was significantly (P < 0.001) associated with increased risk of radiographic progression. Other PRO measures did not meet the statistical criteria for addition to the model.
Twelve-month results from COU-AA-302
Post-treatment there were 99 deaths and 573 radiographic progression events. In individual models, patients with worsening PWB had a 97% higher risk of death versus patients who did not (P ¼ 0.0019). Patients with PRO score worsening had an increased risk of radiographic progression compared with patients who did not have PRO score worsening at 12 months. Increases in risk of radiographic progression were 33% (P ¼ 0.0046), 27% (P ¼ 0.1086), 56% (P < 0.0001) and 22% (P ¼ 0.0525) for pain intensity, FWB, PWB and prostate cancer signs and symptoms, respectively (supplementary Table S2 , available at Annals of Oncology online).
In the multivariate analysis, PWB, the only PRO indicator in COU-AA-302 significantly associated with radiographic progression at 6 months, remained significantly associated with radiographic progression at 12 months post-treatment (supplementary Table S3 , available at Annals of Oncology online). Although a multivariate analysis was not conducted for OS in COU-AA-302 at 6 months, results at 12 months post-treatment were similar to those seen for radiographic progression in that only PWB worsening was added to the model. All other indicators did not meet the criteria and were not added to the models.
Baseline PRO scores also corresponded to OS and rPFS at 6 months post-treatment (supplementary Table S5 , available at Annals of Oncology online); however, the associations were more significant when using change in PRO scores. We then explored the relationship between changes in prognostic laboratory values (hemoglobin, alkaline phosphatase and lactate dehydrogenase) and time-to-event outcome for OS and rPFS. In both studies, a worsening in laboratory values was associated with shorter OS and rPFS at 6 and 12 months post-treatment (supplementary  Tables S6 and S7 , available at Annals of Oncology online). However, the best HRs were no better than the best HRs described above for changes in PROs. Similarly, improvement in laboratory values was associated with reduced risk of death and radiographic progression at 6 and 12 months in COU-AA-301 (supplementary Table S8 , available at Annals of Oncology online), but the best HRs were no better than the best HRs observed for changes in PROs.
Discussion
Results from this analysis demonstrate a relationship between PROs and clinical outcomes in mCRPC. Patients with improved symptom reports during the first 6-12 months were less likely to experience early disease progression or death. The reverse was also true: patients with worsening symptom reports were more likely to experience shortened time to progression or death. This relationship was demonstrated in postdocetaxel as well as chemotherapy-naïve patients-particularly notable because some PRO scores, such as pain prevalence and severity, are typically worse among patients with prior docetaxel exposure and more advanced disease [17] . For example, the mean baseline pain intensity score for the COU-AA-301 population, who had more advanced disease at baseline, was 2.4, whereas it was 0.8 for the COU-AA-302 population, who were asymptomatic or mildly symptomatic at baseline. PRO indicators that were most significantly indicative of clinical outcomes could provide information to treating physicians and payers on the efficacy and efficiency of healthcare. In the postchemotherapy mCRPC population, these indicators were fatigue intensity, FWB, PWB and prostate cancer-specific signs and symptoms for OS, and pain intensity, FWB and PWB for rPFS. In the chemotherapy-naïve mCRPC patients, PWB was most significantly indicative of rPFS.
The relationship between PROs and outcome was detected early: there was a significant association between PROs and improved survival and/or rPFS within 6 months post-treatment. Demonstrating an association between PROs and clinical outcomes early in the treatment course might have beneficial clinical implications, since physicians would be able to consider the clinical significance of their patients' self-reported perspectives and thus better inform diagnostic and treatment decisions that could enhance utilization of resources and thereby positively affect overall healthcare costs. The 12-month post-treatment sensitivity analyses confirmed that the relationships between PROs and outcomes established at 6 months persisted with longer follow-up. 
